Pharmaceutical

Selecta Biosciences files patent for enhanced gene therapy using viral vectors and immunosuppressants

Enhance gene expression and reduce immune responses with Selecta Biosciences' patented method using viral vectors and nanocarriers attached to immunosuppressants. Learn more about this innovative approach for improved therapeutic outcomes.

Mar 13, 2024 - 00:00
Enhance gene expression and reduce immune responses with Selecta Biosciences' patented method using viral vectors and nanocarriers attached to immunosuppressants. Learn more about this innovative approach for improved therapeutic outcomes.
Read the original article

Tags:

Previous Article

Terns scores FDA orphan designation for CML therapy

Next Article

Zealand Pharma files patent for pharmaceutical composition with GLP-1/GLP-2 dual...

What's Your Reaction?

like

dislike

love

funny

angry

sad

wow

Related Posts

STAT+: Leaked study results show a CAR-T from J&J providing big benefit for patients with multiple myeloma

STAT+: Leaked study results show a CAR-T from J&J provi...

Apr 19, 2023

EC expands indication approval for Merck’s Ebola vaccine

EC expands indication approval for Merck’s Ebola vaccine

Sep 9, 2023

‘If we don’t, others will’: White House Covid adviser calls on doctors to combat a vacuum of medical information

‘If we don’t, others will’: White House Covid adviser c...

Apr 3, 2023